VJOncology is committed to improving our service to you

HOPA 2018 | Progression is progression! The importance of monitoring the efficacy of immunotherapy in NSCLC

VJOncology is committed to improving our service to you

Ross Camidge

Recently, due to the revolution of immunotherapy in the treatment of non–small cell lung cancer (NSCLC), more drugs are being licensed to treat patients in the second-line setting. Although overall survival in these patients has been shown to increase, the same can not be said for the rate of progression-free survival. Here, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the importance of carefully monitoring these patients during chemotherapy. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter